Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors

Journal of Cancer Research and Therapeutics

Volumn 5, Issue 4, 2009, Pages 267-271

  Seshadri, Ramakrishnan A ^a   Rajendranath, Rejiv ^a  

^a CANCER INSTITUTE WIA   (India)

Author keywords

Gastrointestinal stromal tumors; Imatinib; Neoadjuvant; Surgery

Indexed keywords

IMATINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MALE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 77749254960     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.59905     Document Type: Article

References (32)

1. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-8.
2. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumors. Lancet Oncol 2002;3:655-64.
3. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, et al. Consensus meeting for the management of gastrointestinal stromal tumors: Report of the GIST consensus conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005;16:566-78.
4. Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Ann Surg 1992;215:68-77.
5. Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: Emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004;11:465-75.
6. Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, et al. Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002;8:3034-8.
7. Kindblom LG, Remotti HE, Aldenborg F, Meis Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152:1259-69.
8. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors. Science 1998;279:577-80.
9. Heinrich MC, Corless CL. Gastric GI stromal tumors (GISTs): The role of surgery in the era of targeted therapy. J Surg Oncol 2005;90:195-207.
10. Crosby JA, Catton CN, Davis A, Couture J, O'Sullivan B, Kandel R, et al. Malignant gastrointestinal stromal tumors of the small intestine: A review of 50 cases from a prospective database. Ann Surg Oncol 2001;8:50-9.
11. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001;136:383-9.
12. Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 2002;38:S37-8.
13. Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Padiola E, Dimitrijevic S et al. Safety and efficacy of imatinib mesylate (STI571) in metastatic gastrointestinal stromal tumors: A phase I study. Lancet 2001;358:1421-3.
14. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts JP, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
15. Bumming P, Andersson J, Meis-Kindblom JM, Klingenstierna H, Engström K, Stierner U, et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumors (GIST) with imatinib: A centre-based study of 17 patients. Br J Cancer 2003;89:460-4.
16. Katz D, Segal A, Alberton Y, Jurim O, Reissman P, Catane R, et al. Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor. Anticancer Drugs 2004;15:599-602.
17. Bonvalot S, Eldweny H, Le Péchoux C, Vanel D, Terrier P, Cavalcanti A, et al. Impact of surgery on advanced Gastrointestinal Stromal Tumors (GIST) in the Imatinib era. Ann Surg Oncol 2006;13:1596-603.
18. Rutkowski P, Nowecki Z, Nyckowski P, Dziewirski W, Grzesiakowska U, Nasierowska-Guttmejer A, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg On col 2006;93:304-11.
19. Hohenberger P, Langer C, Pistorius S, Iesalnieks I, Wardelmann E, Reichardt P, et al. Indication and results of surgery following imatinib treatment of locally advanced or metastatic GI stromal tumors (GIST). J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part-I. Vol 24, No 18S (June 20 Supplement), 2006: 9500.
20. Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, et al. Surgical treatment of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007;14:14-24.
21. Gronchi A, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A, et al. Surgery of residual disease following molecular targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 2007;245:341-6.
22. Cavaliere D, Vagliasindi A, Mura G, Framarini M, Giorgetti G, Solfrini G, et al. Down staging of a gastric GIST by neoadjuvant imatinib and endoscopic assisted laparoscopic resection. Eur J Surg Oncol 2007;33:1044-6.
23. Staiger WI, Ronellenfitsch U, Kaehler G, Schildhaus HU, Dimitrakopoulou-Strauss A, Schwarzbach MH, et al. The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction. World J Surg Oncol 2008;6:37.
24. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.
25. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:5360-7.
26. Choi H, Charnsangavej C, Faria SC, Tamm EP, Benjamin RS, Johnson MM, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG-PET findings. AJR Am J Roentgenol 2004;183:1619-28.
27. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, et al. Response of gastrointestinal stromal tumors (GISTs) to imatinib by Choi criteria and response evaluation criteria in solid tumors (RECIST) as surrogates for survival and time to progression. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part-I. Vol 24, No 18S (June 20 Supplement), 2006: 9508.
28. Loughrey MB, Mitchell C, Mann GB, Michael M, Waring PM. Gastrointestinal stromal tumor treated with neoadjuvant imatinib. J Clin Path 2005;58:779-81
29. Haller F, Detken S, Schulten HJ, Happel N, Gunawan B, Kuhlgatz J, et al. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumors (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol 2007;14:526-32.
30. Lo SS, Papachristou GI, Finkelstein SD, Conroy WP, Schraut WH, Ramanathan RK. Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: Report of a case. Dis Colon Rectum 2005;48:1316-9.
31. Eisenberg BL. Combining imatinib with surgery in gastrointestinal stromal tumors: Rationale and ongoing trials. Clin Colorectal Cancer 2006;6:S24-9.
32. Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009;99:42-7.